Múltiples investigaciones han mejorado el diagnóstico de tuberculosis y otras están en desarrollo. Una sola prueba, recientemente fue aprobada por la OMS, que tiene el potencial para lograr una revolución en el diagnóstico de tuberculosis en enfermos activos y (MDR) TB: GeneXpert® MTB/RIF, la cual aun debido a su elevado coste no ha podido generalizarse al mundo en vías de desarrollo.

Referencias bibliográficas

1. Vidal R. Tuberculosis y micobacteriosis. En: Martín Escribano P, Ramos Seisdedos G, Sanchis Aldás J, editores. Medicina respiratoria. 2.ª ed. Madrid: Aula Médica; 2006. p. 899-923.
2. Palomino JC, Cardoso Leão S, Ritacco V. Tuberculosis 2007. From basic science to patient care. Disponible en:
http://www.tuberculosistextbook.com/tuberculosis2007.pdf. Último acceso junio 2012.
3. World Health Organization (WHO). Global Tuberculosis Control 2010. Geneva, Switzerland: WHO; 2010. Disponible en:
http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf Último acceso junio 2012.
4. Harrington M. From HIV to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis. 2010;50(suppl3):S260-S266.
5. WHO. Global, Regional, and Country-Specific Data for Key Indicators. Geneva, Switzerland: WHO; 2010. Disponible en:
http://www.who.int/tb/publications/global_report/2010/gtbr10_a2.pdf Último acceso junio 2012.
6. Verhagen LM, van den Hof S, van Deutekom H, Hermans PW, Kremer K, Borgdorff MW, et al. Mycobacterial factors relevant for transmission of tuberculosis. J Infect Dis. May 2011;203(9):1249-55
7. Zayas Vinent M. Logros y desafíos de un médico de familia en la gerencia del Programa Nacional de Control de la Tuberculosis. Rev Cubana Med Gen Integr. 2000; 16(5):491-6.
8. Arocha R, Vázquez CM, González M, Leal A. Tuberculosis y SIDA. A propósito de 2 casos. Rev. Cub Med. 2003; 42(2):56-8.
9. Tuberculosis care with TB-HIV co-management: Integrated Management of Adolescent and Adult Illness (IMAI). “WHO/HTM/ HIV/2007.01”, “WHO/HTM/HIV/2007.308”. Geneva: World Health Organization; 2007. p.33.
10. CDC. Trends in Tuberculosis – United States, 2011. Disponible en.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6111a2.htm?s_cid=mm6111a2_w. Último acceso junio 2012.
11. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. Oct 1 2010;51(7):823-9
12. Choi JH, Lee KW, Kang HR, Hwang YI, Jang S, Kim DG, et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest. Feb 2010;137(2):393-400
13. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal Collage of Physicians; 2006. Disponible en:
http://www.rcplondon.ac.uk/pubs/contents/dfb1d46a-bc32-4538-b631 1d82f4b6c8aa. Último acceso junio 2012.
14. Palomino JC, Cardoso Leão S, Ritacco V. Tuberculosis 2007. From basic science to patient care. Disponible en:
http://www.tuberculosistextbook. Com/tuberculosis 2007.pdf. Último acceso junio 2012.
15. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. Apr 1 2010;181(7):743-51
16. Marcelo Pentón JL and Chávez Alfonso MC. Factores de riesgo de tuberculosis pulmonar en el departamento noroeste de Haití. Panorama Cuba y Salud.Vol.2, No.1, ene-abr 2007(3)
17. Carceller A, Lebel MH. Prevención de la tuberculosis en España en el siglo XXI. Anales de Pediatría. Marzo 2005; 62(3):207-9.
18. Domínguez J, Ruiz-Manzano J. Prueba de la tuberculina: ¿es la hora del cambio? Arch Bronconeumol. 2006; 42:47-8.
19. Tuberculosis care with TB-HIV co-management: Integrated Management of Adolescent and Adult Illness (IMAI). “WHO/HTM/ HIV/2007.01”, “WHO/HTM/HIV/2007.308”. Geneva: World Health Organization; 2007. p.33.
20. Caminero Luna JA. Guía de la tuberculosis para médicos especialistas. International union against tuberculosis and lung disease. Paris: Imprimerie Chirat; 2003.
21. Diodio RA, Fujiwara PI, Enarson DA. Should tuberculosis treatment and control be addressed differently in HIV-infected and - uninfected individuals? Eur Respir J. 2005; 25:751-7.
22. Palomino JC, Cardoso Leão S, Ritacco V. Tuberculosis 2007. From basic science to patient care. Disponible en:
http://www.tuberculosistextbook.com/tuberculosis 2007.pdf. Último acceso junio 2012.
23. Geng E, Kreiswirth B, Burzynski J, Schluger NW. Clinical and radiographic correlates of primary and reactivation tuberculosis. JAMA. 2005; 293:2740-5.
24. Waite S, Jeudy J, White CS. Acute lung infections in normal andimmunocompromise hosts. Radiol Clin N Am. 2006; 44:295-315.
25. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004; 1: CD000171.
26. Domínguez J, Ruiz-Manzano J, De Souza-Galvão M, Latorre I, Milà C, Blanco S, et al. Comparison of two commercially available interferon-gamma blood tests for immunodiagnosis of tuberculosis infection. Clin Vaccine Immunol. 2008; 15:168-71.
27. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146:340-54.
28. Catanzaro A, Perry S, Clarridge JE, Dunbar S, Goodnight-White S, LoBoue PA, et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA. 2000; 283:639-45.
29. Caminero J A, Medina M V, Rodríguez de Castro F, Cabrera P. Tuberculosis y otras micobacteriosis. En: Caminero J A, Fernández Fau L. Manual de Neumología y Cirugía Torácica. Madrid: EDIMPSA, 1998.
30. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC, and guidelines for using the QuantiFERON®-TBGold test for detecting Mycobacterium tuberculosis infection,United States. MMWR Morb Mortal Wkly Rep. 2005; 54(RR-15):1-55.
31. Helb D, Jones M, Story E. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48:229-237
32. Jafari C, Thijsen S, Sotgiu G, Goletti D, Domínguez Benítez JA, Losi M, et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med. Oct 1 2009;180(7):666-73
33. Somocurcio JG, Sotomayor A, Shin S, Portilla S, Valcarcel M, Guerra D, et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax. 2007; 62:416-21
34. Boehme CC, Nicol MP, Nabeta P. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377:1495-1505.